Plenary Sessions and Speakers

Get a sneak peek below at the exciting keynote lectures and plenary sessions that will be part of the IPVC 2023 scientific program. Please note that all sessions are going to be LIVE. All times below are in Washington DC Local Time – EDT (GMT-4).

If you want to be the first to know all IPVC 2023 updates, sign up for our newsletter here.

Tuesday, April 18 16:00-17:30

OPENING PLENARY AND INTRODUCTION TO IPVC

  • Comparing and contrasting Covid-19 control with HPV control and elimination

Dr. Barney Graham, USA
Wednesday, April 19 11:00-12:30

PLENARY SESSION 2

  • One-dose HPV vaccination overview and a focus on the KENSHE data

Dr. Ruanne Barnabas, USA

  • New prophylactic HPV vaccines

Prof. Richard Roden, USA

  • Therapeutic vaccines in particular with clinical outcomes such as CIN 3

Prof. Mayumi Nakagawa, USA
Thursday, April 20 8:30-10:00

PLENARY SESSION 3

  • Lessons learned from other disease control programs such as HIV

Prof. Helen Rees, South Africa

  • What can we learn from the hepatitis B model in elimination of HPV-related diseases?

Dr. Mark Kane, USA

  • Anal cancer control approaches

Prof. Joel Palefsky, USA

 

16:40-18:10

PLENARY SESSION 4

  • Mastomys Coucha: a unique animal model for papillomavirus-induced skin carcinogenesis

Dr. Frank Rosl, Germany

  • Pros and cons of Beta HPVs as causative agents in skin cancer

Dr. Denise Galloway, USA

  • Epidemiology and biology of Beta human papillomavirus types

Dr. Massimo Tommasino, Italy
Friday, April 21 11:00-12:30

PLENARY SESSION 5

  • Covid-19 effect on cervical screening

Dr. Mona Saraiya, USA

  • Re-invigorating efforts towards cervical cancer elimination: mitigating the impact of Covid-19

Prof. Karen Canfell, Australia

  • What will it take (and how to) achieve cervical cancer elimination goal by 2030 with a perspective for low and middle income countries?

Prof. Yin Ling Woo, Malaysia

 

16:30-18:00

CLOSING PLENARY

  • The future is now

Dr. Douglas Lowy, USA
Tuesday,
April 18		 16:30-18:00

OPENING CEREMONY AND KEYNOTE LECTURE

  • Comparing and Contrasting COVID-19 Control with HPV Control and Elimination

Barney Graham, USA
Wednesday,
April 19		 11:00-12:30

PLENARY SESSION 1

  • One-dose HPV vaccination overview and a focus on the KENSHE data

Ruanne Barnabas, USA

  • New prophylactic HPV vaccines

Richard Roden, USA

  • Therapeutic vaccines in particular with clinical outcomes such as CIN 3

Mayumi Nakagawa, USA
Thursday,
April 20		 8:30-10:00

PLENARY SESSION 2

  • Lessons learned from other disease control programs such as HIV

Helen Rees, South Africa

  • What can we learn from the hepatitis B model in elimination of HPV-related diseases?

 Mark Kane, USA

  • Anal cancer control approaches

Joel Palefsky, USA

 

16:40-18:00

PLENARY SESSION 3

  • Mastomys Coucha: a unique animal model for papillomavirus-induced skin carcinogenesis

Frank Rosl, Germany

  • Pros and cons of Beta HPVs as causative agents in skin cancer

Denise Galloway, USA

*Special Tribute to Massimo Tommasino on his work on Epidemiology and Biology of Beta Human Papillomavirus Types
Friday,
April 21		 11:45-13:15

PLENARY SESSION 4

  • Covid-19 effect on cervical screening

Mona Saraiya, USA

  • Re-invigorating efforts towards cervical cancer elimination: mitigating the impact of Covid-19

Karen Canfell, Australia

  • What will it take (and how to) achieve cervical cancer elimination goal by 2030 with a perspective for low and middle income countries?

Yin Ling Woo, Malaysia

 

16:00-17:15

CLOSING CEREMONY AND KEYNOTE LECTURE

  • The future is now

 Douglas Lowy, USA

Tuesday, November 16, 2021
15:30-17:15

Successful vaccines – what’s the secret?
Prof. Mark K. Slifka, USAWednesday, November 17, 2021
14:30-16:00

Public trust in vaccines 
Dr. Maya J. Goldenberg, Canada

Immunotherapy for HPV
Dr. Sjoerd van der Burg, Netherlands

Next-generation HPV vaccines integrating biology and engineering
Dr. Robert L. Garcea, USAThursday, November 18, 2021
10:00-11:30

Inequity in global access to health and justice
Dr. Gina Ogilvie. Canada

Global HPV vaccine supply & demand and the impact of the COVID-19 pandemic
Dr. Tania Cernuschi, Switzerland

Cervical cancer prevention and management as part of comprehensive sexual and reproductive health care for women in sub-Saharan Africa
Dr. Peter Jay Hotez, USAThursday, November 18, 2021
14:30-15:30

HNSCC development and progression: Avenues for therapeutic development 
Dr. Jennifer R. Grandis, USA

RRP: the paradigm for HPV immune evasion
Dr. Vincent R. Bonagura, USAFriday, November 19, 2021
10:30-11:30

Exploiting DNA damage repair by HPV
Prof. Laimonis A Laimins, USA

Vaginal and anal microbiome 
Prof. Adam Burgener, USAFriday, November 19, 2021
15:30-17:00

Research in HPV: past, present, and future
Dr. Eduardo Franco, CanadaScientific Program